Literature DB >> 11493035

Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.

O V Anichtchik1, N Peitsaro, J O Rinne, H Kalimo, P Panula.   

Abstract

Parkinson's disease (PD) is a brain degenerative disorder with unknown etiology, and specific degeneration of mesencephalic dopaminergic cells is a morphological manifestation of the disease. The central histaminergic system appears to be activated in PD, since the histaminergic innervation is increased in the substantia nigra. The aim of the present study was to investigate the expression and function of histamine H(3) receptors in PD, using receptor mRNA in situ hybridization with oligonucleotide probes, receptor binding assay with a specific radioactive agonist, and GTP-gamma-[(35)S]-binding assay as a tool to study the activation of the receptor G-protein. H(3) receptor binding sites were detected using N-alpha-methylhistamine autoradiography in the basal ganglia and cortex, being most abundant in the substantia nigra and striatum. In PD substantia nigra we detected an increase of the receptor binding density. In situ hybridization study of the receptor mRNA revealed prominent sites of H(3) receptor synthesis in the putamen, cortex, and globus pallidus, whereas very low mRNA expression was seen in the substantia nigra. In the PD pallidum externum, H(3) receptor mRNA expression was elevated as compared with the normal brains. GTP-gamma-[(35)S]-binding assay did not reveal any significant difference between PD and normal brains, although the density values in PD substantia nigra tended to be lower than in the normal brain, and density values in PD striatum were higher. The dopaminergic neurons did not express significant amount of H(3) receptor mRNA, suggesting that the effects of H(3) receptor-mediated modulation of dopamine release are indirect. Our data indicates modulation of the histamine H(3) receptor in PD at the level of the mRNA expression in the striatum and receptor density in the substantia nigra. The receptor activity seems to be unchanged or decreased, as revealed by GTP-gamma-[(35)S]-binding assay. Modulation of the histamine H(3) receptor may influence the activity of other neurotransmitter systems, e.g., the GABAergic one, in the substantia nigra. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493035     DOI: 10.1006/nbdi.2001.0413

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  28 in total

1.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.

Authors:  Przemyslaw Nowak; Aleksandra Bortel; Joanna Dabrowska; Izabela Biedka; Grzegorz Slomian; Wojciech Roczniak; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

3.  Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function.

Authors:  Carla Ferrada; Sergi Ferré; Vicent Casadó; Antonio Cortés; Zuzana Justinova; Chanel Barnes; Enric I Canela; Steven R Goldberg; Rob Leurs; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-05-16       Impact factor: 5.250

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 5.  The histamine H3 receptor: from discovery to clinical trials with pitolisant.

Authors:  Jean-Charles Schwartz
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  Histamine Excites Striatal Dopamine D1 and D2 Receptor-Expressing Neurons via Postsynaptic H1 and H2 Receptors.

Authors:  Qian-Xing Zhuang; Han-Ting Xu; Xu-Juan Lu; Bin Li; Wing-Ho Yung; Jian-Jun Wang; Jing-Ning Zhu
Journal:  Mol Neurobiol       Date:  2018-03-01       Impact factor: 5.590

7.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation.

Authors:  J Vanhanen; S Nuutinen; M Lintunen; T Mäki; J Rämö; K Karlstedt; P Panula
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

9.  Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata.

Authors:  Sarah Threlfell; Stephanie J Cragg; Imre Kalló; Gergely F Turi; Clive W Coen; Susan A Greenfield
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

10.  Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.

Authors:  A D Medhurst; J C Roberts; J Lee; C P L-H Chen; S H Brown; S Roman; M K P Lai
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.